S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
His system isolated NVIDIA - Here's His Next Buy. (Ad)
2 Stocks to Benefit from the Aging Population
3 Warren Buffett Stocks that are Moving into the Buy Zone
BREAKING: The truth about war with China (Ad)
3 Reasons Unity Software Is Ready to Rally 38%
3 Stocks That Really, Really Need the Defense Bill to Pass
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Is Hanes Worth More than the Sum of Its Parts?
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
His system isolated NVIDIA - Here's His Next Buy. (Ad)
2 Stocks to Benefit from the Aging Population
3 Warren Buffett Stocks that are Moving into the Buy Zone
BREAKING: The truth about war with China (Ad)
3 Reasons Unity Software Is Ready to Rally 38%
3 Stocks That Really, Really Need the Defense Bill to Pass
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Is Hanes Worth More than the Sum of Its Parts?
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
His system isolated NVIDIA - Here's His Next Buy. (Ad)
2 Stocks to Benefit from the Aging Population
3 Warren Buffett Stocks that are Moving into the Buy Zone
BREAKING: The truth about war with China (Ad)
3 Reasons Unity Software Is Ready to Rally 38%
3 Stocks That Really, Really Need the Defense Bill to Pass
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Is Hanes Worth More than the Sum of Its Parts?
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
His system isolated NVIDIA - Here's His Next Buy. (Ad)
2 Stocks to Benefit from the Aging Population
3 Warren Buffett Stocks that are Moving into the Buy Zone
BREAKING: The truth about war with China (Ad)
3 Reasons Unity Software Is Ready to Rally 38%
3 Stocks That Really, Really Need the Defense Bill to Pass
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Is Hanes Worth More than the Sum of Its Parts?
NASDAQ:DRRX

DURECT (DRRX) Stock Forecast, Price & News

$2.63
-0.06 (-2.23%)
(As of 09/26/2023 ET)
Compare
Today's Range
$2.57
$2.84
50-Day Range
$2.63
$4.92
52-Week Range
$2.57
$9.50
Volume
631,590 shs
Average Volume
160,692 shs
Market Capitalization
$72.59 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$34.25

DURECT MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,202.3% Upside
$34.25 Price Target
Short Interest
Bearish
7.99% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.19
Upright™ Environmental Score
News Sentiment
1.25mentions of DURECT in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.76) to ($1.48) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.07 out of 5 stars

Medical Sector

569th out of 964 stocks

Pharmaceutical Preparations Industry

252nd out of 445 stocks


DRRX stock logo

About DURECT (NASDAQ:DRRX) Stock

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.

DRRX Price History

DRRX Stock News Headlines

Short Interest in DURECT Co. (NASDAQ:DRRX) Rises By 19.2%
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
DURECT (NASDAQ:DRRX) Rating Lowered to Sell at StockNews.com
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
Earnings Outlook For Durect
Analyst Ratings for Durect
8-K: DURECT CORP
Durect: Q1 Earnings Snapshot
See More Headlines
Receive DRRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DURECT and its competitors with MarketBeat's FREE daily newsletter.

DRRX Company Calendar

Last Earnings
8/09/2023
Today
9/27/2023
Next Earnings (Estimated)
11/01/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:DRRX
Employees
72
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$34.25
High Stock Price Forecast
$41.00
Low Stock Price Forecast
$27.00
Forecasted Upside/Downside
+1,202.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-35,330,000.00
Net Margins
-185.87%
Pretax Margin
-185.87%

Debt

Sales & Book Value

Annual Sales
$19.28 million
Book Value
$1.10 per share

Miscellaneous

Free Float
26,413,000
Market Cap
$72.59 million
Optionable
Optionable
Beta
1.49
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Dr. James E. Brown D.V.M. (Age 66)
    Co-Founder, CEO, Pres & Director
    Comp: $885.86k
  • Ms. Judy R. Joice (Age 66)
    Sr. VP of Operations & Corp. Quality Assurance
    Comp: $451.82k
  • Dr. Norman L. Sussman M.D. (Age 70)
    Chief Medical Officer
    Comp: $587.95k
  • Mr. Timothy M. Papp M.B.A. (Age 47)
    CFO & Sec.
  • Ms. Jian Li M.B.A. (Age 53)
    Interim Principal Accounting Officer, Sr. VP of Fin., Corp. Controller & Sec.
  • Dr. WeiQi Lin M.D.
    Ph.D., Exec. VP of R&D and Principal Scientist
  • Mr. Keith L. Lui M.B.A.
    Sr. VP of Bus. Devel., Commercial & Medical Affairs
  • Dr. Su Il Yum Ph.D. (Age 84)
    Exec. Officer













DRRX Stock - Frequently Asked Questions

Should I buy or sell DURECT stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for DURECT in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" DRRX shares.
View DRRX analyst ratings
or view top-rated stocks.

What is DURECT's stock price forecast for 2023?

4 brokerages have issued twelve-month price targets for DURECT's shares. Their DRRX share price forecasts range from $27.00 to $41.00. On average, they anticipate the company's stock price to reach $34.25 in the next twelve months. This suggests a possible upside of 1,202.3% from the stock's current price.
View analysts price targets for DRRX
or view top-rated stocks among Wall Street analysts.

How have DRRX shares performed in 2023?

DURECT's stock was trading at $3.46 at the beginning of 2023. Since then, DRRX stock has decreased by 24.0% and is now trading at $2.63.
View the best growth stocks for 2023 here
.

When is DURECT's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our DRRX earnings forecast
.

How were DURECT's earnings last quarter?

DURECT Co. (NASDAQ:DRRX) announced its quarterly earnings data on Wednesday, August, 9th. The specialty pharmaceutical company reported ($0.46) EPS for the quarter, missing analysts' consensus estimates of ($0.45) by $0.01. The specialty pharmaceutical company earned $2.08 million during the quarter, compared to analyst estimates of $2.89 million. DURECT had a negative net margin of 185.87% and a negative trailing twelve-month return on equity of 179.02%.

When did DURECT's stock split?

DURECT shares reverse split on the morning of Tuesday, December 6th 2022. The 1-10 reverse split was announced on Tuesday, December 6th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, December 6th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of DURECT own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DURECT investors own include Geron (GERN), Catalyst Pharmaceuticals (CPRX), VBI Vaccines (VBIV), MannKind (MNKD), Novavax (NVAX), Cassava Sciences (SAVA), Amarin (AMRN), Matinas BioPharma (MTNB), Inovio Pharmaceuticals (INO) and Verastem (VSTM).

What is DURECT's stock symbol?

DURECT trades on the NASDAQ under the ticker symbol "DRRX."

Who are DURECT's major shareholders?

DURECT's stock is owned by a variety of retail and institutional investors. Top institutional investors include Ingalls & Snyder LLC (6.10%), CM Management LLC (1.92%), Renaissance Technologies LLC (1.48%), BlackRock Inc. (1.46%), Beirne Wealth Consulting Services LLC (1.15%) and Geode Capital Management LLC (0.95%). Insiders that own company stock include Gail J Maderis, Gail M Farfel, Judith J Robertson, Judy R Joice, Mohammad Azab and Simon X Benito.
View institutional ownership trends
.

How do I buy shares of DURECT?

Shares of DRRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is DURECT's stock price today?

One share of DRRX stock can currently be purchased for approximately $2.63.

How much money does DURECT make?

DURECT (NASDAQ:DRRX) has a market capitalization of $72.59 million and generates $19.28 million in revenue each year. The specialty pharmaceutical company earns $-35,330,000.00 in net income (profit) each year or ($1.54) on an earnings per share basis.

How can I contact DURECT?

DURECT's mailing address is 10260 BUBB RD, CUPERTINO CA, 95014. The official website for the company is www.durect.com. The specialty pharmaceutical company can be reached via phone at (408) 777-1417, via email at mike.arenberg@durect.com, or via fax at 408-777-3577.

This page (NASDAQ:DRRX) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -